EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pre-Treatment with Dacarbazine Sensitizes B16 Melanoma to CAR T Cell Therapy in Syngeneic Mouse Model

Egor A Emelianov iD, Elizaveta R Naberezhnaya iD, Andrey S Logvinov, Valeria M Stepanova iD, Aleksandr S Chernov iD, Yuliana A Mokrushina iD, Diana M Malabuiok iD, Dmitry E Pershin, Ekaterina A Malakhova, Elena A Kulakovskaya, Tatiana N Prokofeva, Victor V Tatarskiy iD und 6 weitere

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms27010189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Egor A Emelianov und 17 weiteren Autor:innen. Beteiligte Einrichtung: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia. Hauptthemen laut MEDLINE: Dacarbazine, Immunotherapy, Adoptive, Melanoma, Experimental, Receptors, Chimeric Antigen. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: to Y.P. Rubtsov by Russian Scientific Foundation., Russian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adoptive cell therapy (ACT) with T cells modified with a chimeric antigen receptor (CAR T cells) has dramatically improved outcomes in hematologic cancers. However, its efficacy in solid tumors, such as melanoma, is hampered by several factors. These include heterogeneous expression of tumor-associated antigens (TAA) and an immunosuppressive, profibrotic tumor microenvironment (TME), which restricts cytotoxic CAR T cells trafficking into the tumor, as well as their persistence and cytolytic activity. As a result, responses to CAR T cell monotherapy in melanoma and other solid tumors are typically weak, transient or even absent. Emerging evidence suggests that combining traditional chemotherapy with CAR T cell therapy can enhance the antitumor activity of CAR T cells in solid malignancies. Partial tumor cell killing by chemotherapy improves access to TAA and disrupts the TME by affecting the global structure of the tumor tissue. Here, we developed an immunocompetent syngeneic B16 melanoma mouse model to test a combination of classical dacarbazine (DTIC) chemotherapy with ACT with murine CAR T cells. B16-F10 (next as B16) melanoma cells were modified to express a human/murine hybrid epidermal growth factor receptor (EGFR) recognized by a murine CAR bearing a single-chain variable fragment (scFv) derived from cetuximab, an anti-EGFR monoclonal antibody approved for the treatment of colorectal and certain other solid tumors. Prior to CAR T cells administration, cyclophosphamide (CPA) pre-conditioning was used. We demonstrated that DTIC therapy followed by infusion of murine CAR T cells targeting the human/murine hybrid EGFR (EGFR mCAR T cells) provided superior tumor control and prolonged survival compared to monotherapy with either DTIC or EGFR mCAR T cells alone. These findings support the potential feasibility of a combined therapeutic strategy for human melanoma involving DTIC treatment followed by EGFR CAR T cells infusion after CPA pre-conditioning.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DacarbazineImmunotherapy, AdoptiveMelanoma, ExperimentalReceptors, Chimeric AntigenAntineoplastic Agents, AlkylatingAnimalsMiceHumansCell Line, TumorMice, Inbred C57BLTumor MicroenvironmentDisease Models, AnimalErbB ReceptorsFemaleT-Lymphocytes

Stichwörter der Autor:innen

B16 melanomacombined melanoma therapydacarbazinemurine CAR T cellssyngeneic mouse modeltumor microenvironment

Substanzen

DacarbazineReceptors, Chimeric AntigenErbB ReceptorsAntineoplastic Agents, Alkylating

Autor:innen und Institutionen

  • Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
  • Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, 117997 Moscow, Russia.
  • Laboratory of Molecular Oncobiology, Institute of Gene Biology, 34/5 Vavilova Street, 119334 Moscow, Russia.
  • N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation, 115522 Moscow, Russia.

ORCID-Profile: Egor A Emelianov, Elizaveta R Naberezhnaya, Valeria M Stepanova, Aleksandr S Chernov, Yuliana A Mokrushina, Diana M Malabuiok, Victor V Tatarskiy, Sergey M Deyev, Alexander G Gabibov, Yury P Rubtsov, Dmitry V Volkov

Förderung

  • to Y.P. Rubtsov by Russian Scientific Foundation.
  • Russian Science Foundation

Zitieren

APA

Emelianov, E. A., Naberezhnaya, E. R., Logvinov, A. S., Stepanova, V. M., Chernov, A. S., Mokrushina, Y. A., Malabuiok, D. M., Pershin, D. E., Malakhova, E. A., Kulakovskaya, E. A., Prokofeva, T. N., Tatarskiy, V. V., Shramova, E. I., Deyev, S. M., Gabibov, A. G., Kushlinskii, N. E., Rubtsov, Y. P., & Volkov, D. V. (2025). Pre-Treatment with Dacarbazine Sensitizes B16 Melanoma to CAR T Cell Therapy in Syngeneic Mouse Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27010189

Vancouver

Emelianov EA, Naberezhnaya ER, Logvinov AS, Stepanova VM, Chernov AS, Mokrushina YA, et al. Pre-Treatment with Dacarbazine Sensitizes B16 Melanoma to CAR T Cell Therapy in Syngeneic Mouse Model. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms27010189

BibTeX
@article{Emelianov2025,
  author = {Emelianov, Egor A and Naberezhnaya, Elizaveta R and Logvinov, Andrey S and Stepanova, Valeria M and Chernov, Aleksandr S and Mokrushina, Yuliana A and Malabuiok, Diana M and Pershin, Dmitry E and Malakhova, Ekaterina A and Kulakovskaya, Elena A and Prokofeva, Tatiana N and Tatarskiy, Victor V and Shramova, Elena I and Deyev, Sergey M and Gabibov, Alexander G and Kushlinskii, Nikolay E and Rubtsov, Yury P and Volkov, Dmitry V},
  title = {Pre-Treatment with Dacarbazine Sensitizes B16 Melanoma to CAR T Cell Therapy in Syngeneic Mouse Model},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms27010189}
}
Kostenlos starten →